Australia markets closed
  • ALL ORDS

    7,552.10
    -40.60 (-0.53%)
     
  • AUD/USD

    0.7565
    +0.0012 (+0.16%)
     
  • ASX 200

    7,298.50
    -43.70 (-0.60%)
     
  • OIL

    73.38
    +0.53 (+0.73%)
     
  • GOLD

    1,781.80
    +4.40 (+0.25%)
     
  • BTC-AUD

    44,930.54
    +2,909.11 (+6.92%)
     
  • CMC Crypto 200

    813.96
    +19.63 (+2.47%)
     

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Report 2021: Serotonin Receptor Antagonist is Projected to Account for $1.2 Billion of the Total $3.2 Billion Market by 2027 - ResearchAndMarkets.com

·4-min read

The "Chemotherapy-induced Nausea and Vomiting Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Reach $3.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Chemotherapy-induced Nausea and Vomiting Drugs estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027.

Serotonin Receptor Antagonist, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurokinin NK1 Receptor Antagonist segment is readjusted to a revised 5.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $667.6 Million, While China is Forecast to Grow at 4.8% CAGR

The Chemotherapy-induced Nausea and Vomiting Drugs market in the U.S. is estimated at US$667.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$565.6 Million by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Dopamine Antagonist Segment to Record 4.8% CAGR

In the global Dopamine Antagonist segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$294.1 Million in the year 2020 will reach a projected size of US$409.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$368.2 Million by the year 2027.

Select Competitors (Total 41 Featured):

  • Acacia Pharma Group Plc

  • Aphios Corporation

  • Baxter International Inc.

  • Dr. Reddy's Laboratories Ltd.

  • Eisai Co., Ltd.

  • Especificos Stendhal S.A. DE C.V.

  • F. Hoffmann-La Roche AG

  • GlaxoSmithKline PLC

  • Helsinn Healthcare SA

  • Heron Therapeutics, Inc.

  • Kyowa Hakko Kirin Co., Ltd.

  • Lee's Pharmaceutical Holdings Ltd.

  • Merck & Co., Inc.

  • Midatech Pharma PLC

  • Mundipharma Pte., Ltd.

  • Mylan N.V.

  • Ono Pharmaceutical Co., Ltd.

  • Opko Health, Inc.

  • Orchid Chemicals & Pharmaceuticals Ltd

  • Otsuka Pharmaceutical Co., Ltd.

  • Purdue Pharma LP

  • Sandoz International GmbH

  • SciClone Pharmaceuticals, Inc.

  • Shin Nippon Biomedical Laboratories Ltd. (SNBL)

  • Solasia Pharma K.K.

  • Specialised Therapeutics Asia Pte Ltd

  • Sun Pharmaceutical Industries Ltd.

  • Taiho Pharmaceutical Co., Ltd.

  • Tesaro, Inc.

  • Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

  • World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Serotonin Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Neurokinin NK1 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Dopamine Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Benzodiazepine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 41

For more information about this report visit https://www.researchandmarkets.com/r/lqcwi9

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005514/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting